NasdaqGM:RAPPPharmaceuticals
How Rapport’s Greater China RAP-219 Licensing Deal At Rapport Therapeutics (RAPP) Has Changed Its Investment Story
In March 2026, Rapport Therapeutics announced it had granted Tenacia Biotechnology exclusive rights to develop and commercialize its investigational drug RAP-219 in Greater China, in exchange for a US$20,000,000 upfront payment, up to about US$308,000,000 in potential milestones and other payments, and tiered royalties on future regional sales.
Beyond the financial terms, the agreement positions Tenacia to lead Phase 3 trial sites in China for RAP-219 in focal onset seizures, potentially...